Xifaxan
Product Images NDC 68258-1107

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Xifaxan (NDC 68258-1107). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ndc 68258-1107-xx (Ndc 68258 1107 Xx Salix)

Ndc 68258-1107-xx (Ndc 68258 1107 Xx      Salix)
This is a description of two different pharmaceutical products. The first, a pink-colored round biconvex tablet with the inscription "SX", dispensed by Salix Pharmaceuticals, Inc. with the product ID 65649-0301-03, is to be taken orally according to the doctor's prescription. The second is Xifaxan 200 mg tablets with product #1107-X containing Rifamixin. They are packaged exclusively by Dispensing Solutions in Santa Ana, CA 92704, and are available in XX tablets, bearing lot number "SAMPLE EXP:00-00" and RX# 33710186. The tablets must be kept out of children's reach, and the storage temperature should be between 68°-77°F.*
FDA Label Image

Xifaxan Structural Formula (Xifaxan 1)

FDA Label Image

Kaplan-meier Event-free Curves Graph (Xifaxan 2)

FDA Label Image

Kaplan-meier Event-free Curves_pivotalhestudy (Xifaxan 3)

Kaplan-meier Event-free Curves_pivotalhestudy (Xifaxan 3)
This is a statistical report on a clinical trial comparing the effectiveness of a placebo treatment. The hazard ratio of the placebo treatment is reported to be 0.5, indicating a lower risk of the event in the placebo group compared to the other treatment group. The trial involved 954 participants and the logrank p-value was reported to be 0.0129, suggesting a significant difference between the placebo and other treatment groups. However, the remaining text appears to be incomplete or unreadable, except for the label "Days Post-randomization".*
FDA Label Image

Salix-logo (Xifaxan 4)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.